Get the Stockscreener App
15.06
1.82%
-0.305
Mbx Biosciences Inc stock is traded at $15.06, with a volume of 8,517.
It is down -1.82% in the last 24 hours and up +3.57% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$15.37
Open:
$15.39
24h Volume:
8,517
Relative Volume:
0.02
Market Cap:
$501.56M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-9.6244
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
+10.71%
1M Performance:
+3.57%
6M Performance:
+53.67%
1Y Performance:
+0.00%
1-Day Range:
$14.73
$15.39
1-Week Range:
$12.98
$15.46
52-Week Range:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
14.93 | 466.62M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.41 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.46 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.54 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
705.80 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
299.68 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Breakout Traders Target MBX Biosciences Inc. on Recovery Setup getLinesFromResByArray error: size == 0 - 더경남뉴스
MBX Biosciences Up 15%, Insider Buyers Are Up 53% - simplywall.st
Why MBX Biosciences Inc. is moving todayEarnings Recap Report & Smart Money Movement Tracker - Newser
What is MBX Biosciences Inc.’s book value per share getLinesFromResByArray error: size == 0 - 더경남뉴스
Volume spikes in MBX Biosciences Inc. stock – what they meanJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - Newser
Applying Wyckoff theory to MBX Biosciences Inc. stockEarnings Risk Summary & Fast Entry High Yield Tips - Newser
Risk vs reward if holding onto MBX Biosciences Inc.Analyst Downgrade & High Conviction Buy Zone Alerts - Newser
Does MBX Biosciences Inc. show high probability of reboundJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - Newser
Forecasting MBX Biosciences Inc. price range with options data2025 Breakouts & Breakdowns & Growth Focused Stock Pick Reports - Newser
How to recover losses in MBX Biosciences Inc. stockWeekly Stock Analysis & Free Community Supported Trade Ideas - Newser
When is the best time to exit MBX Biosciences Inc.2025 Performance Recap & Real-Time Chart Breakout Alerts - Newser
MBX Biosciences Inc. stock daily chart insightsWeekly Profit Report & Weekly Breakout Opportunity Watchlist - Newser
Will MBX Biosciences Inc. rebound enough to break even2025 Support & Resistance & Verified Short-Term Trading Plans - Newser
MBX Biosciences Inc. stock retracement – recovery analysisWeekly Investment Summary & Fast Entry High Yield Stock Tips - Newser
What’s the recovery path for long term holders of MBX Biosciences Inc.Exit Point & Verified High Yield Trade Plans - Newser
Can swing trading help recover from MBX Biosciences Inc. losses2025 Market Trends & AI Forecasted Entry and Exit Points - Newser
MBX Biosciences Inc. stock prediction for this week2025 Historical Comparison & Stepwise Swing Trade Plans - Newser
What high frequency data says about MBX Biosciences Inc.2025 Market Outlook & Verified Momentum Stock Alerts - Newser
Evaluating MBX Biosciences Inc. with trendline analysisJuly 2025 Big Picture & Growth-Oriented Investment Plans - Newser
Can volume confirm reversal in MBX Biosciences Inc.Trade Entry Summary & Target Return Focused Stock Picks - Newser
Update Report: How liquid is MBX Biosciences Inc. stockJuly 2025 Setups & Free High Return Stock Watch Alerts - theviewers.co.kr
Published on: 2025-08-23 17:39:45 - 더경남뉴스
Published on: 2025-08-23 07:21:30 - beatles.ru
Chartists See Breakout Potential in MBX Biosciences Inc.2025 Trade Ideas & Free Fast Entry Momentum Trade Alerts - beatles.ru
MBX Biosciences Submits IND for Once-Monthly Obesity Drug - MSN
MBX Biosciences Insiders Added US$579.8k Of Stock To Their Holdings - Yahoo Finance
Screener Results Flag MBX Biosciences Inc. as OversoldTrade Risk Summary & Long-Term Growth Portfolio Plans - mustnews.co.kr
Is MBX Biosciences Inc. forming a reversal pattern2025 AllTime Highs & High Accuracy Swing Trade Signals - Newser
Volume Profile Shows Strong Base for MBX Biosciences Inc.July 2025 Trends & Capital Efficient Trade Techniques - 더경남뉴스
Breakout Traders Target MBX Biosciences Inc. on Recovery SetupWeekly Profit Report & Stock Portfolio Risk Management - newsimpact.co.kr
What to do if you’re stuck in MBX Biosciences Inc.July 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
MBX Biosciences Inc. recovery potential after sell offWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Is MBX Biosciences Inc. stock a good hedge against inflationWeekly Trade Report & Risk Controlled Swing Alerts - Newser
What’s next for MBX Biosciences Inc. stock priceInsider Buying & Long Hold Capital Preservation Plans - Newser
What makes MBX Biosciences Inc. stock price move sharplyTrade Volume Summary & Weekly Market Pulse Alerts - thegnnews.com
Published on: 2025-08-17 01:37:02 - Newser
Is MBX Biosciences Inc. a strong growth stock2025 Geopolitical Influence & Accurate Buy Signal Notifications - thegnnews.com
How to track smart money flows in MBX Biosciences Inc.Take Profit & Risk Adjusted Buy and Sell Alerts - Newser
Can a trend reversal in MBX Biosciences Inc. lead to recovery2025 Market Overview & Fast Moving Stock Watchlists - Newser
Technical analysis overview for MBX Biosciences Inc. stockWeekly Risk Summary & Growth Focused Stock Pick Reports - Newser
MBX Biosciences stock rating initiated at Buy by Jefferies with $36 target - Investing.com
Using economic indicators to assess MBX Biosciences Inc. potentialMarket Sentiment Report & Weekly Momentum Picks - Newser
Jefferies Maintains "Buy" Rating for MBX Biosciences with $36 Price Target. - AInvest
MBX Biosciences assumed with a Buy at Jefferies - TipRanks
MBX Biosciences: Jefferies upgrades to Buy, raises price target to $36. - AInvest
MBX Biosciences (MBX) and Its Competitors Critical Survey - Defense World
Published on: 2025-08-14 21:34:07 - Newser
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mbx Biosciences Inc Stock (MBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
1.46%
7.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):